UL Solutions Inc.

ULS ·Healthcare, Diagnostics & Research, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022
Operating Activities
Net Income $325.0M $326.0M $260.0M $293.0M
Depreciation & Amortization $188.0M $172.0M $154.0M $135.0M
Depreciation $110.0M $100.0M $88.0M $75.0M
Amortization $13.0M $13.0M $15.0M $16.0M
Stock-Based Compensation $47.0M $23.0M $0 $0
Net Cash from Operating Activities $600.0M $524.0M $467.0M $372.0M
Investing Activities
Capital Expenditures $197.0M $237.0M $215.0M $164.0M
Business Acquisitions $1.0M $26.0M $18.0M $66.0M
Net Cash from Investing Activities $-204.0M $-234.0M $-175.0M $-238.0M
Financing Activities
Dividends Paid $104.0M $100.0M $680.0M $1.60B
Stock Repurchases
Net Cash from Financing Activities $-396.0M $-284.0M $-294.0M $-1.12B
Net Change in Cash $-3.0M $-17.0M $-7.0M $-1.01B
Free Cash Flow $403.0M $287.0M $252.0M $208.0M